Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $100
Ionis Pharmaceuticals, Inc. -0.45%
Ionis Pharmaceuticals, Inc. IONS | 74.79 | -0.45% |
Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals (NASDAQ:
IONS) with a Overweight and raises the price target from $87 to $100.
